Eric Lefkofsky is a philanthropist in the USA. He majorly focuses on using his money to do helpful projects for the society. His philanthropy work has contributed greatly to the health sector in the USA. He is the founder of Campus Company.
The campus is a company that has been in the forefront in battling with cancer. The company has invested greatly in technology which is very helpful in the fight against cancer. The company has brought a very great impact on the health of the people living in the USA because of this spirited fight against cancer.
In 2006, Eric Lefkofsky together with his wife Liz opened a private charitable foundation. The foundation was given the name Lefkofsky Family Foundation. The main aim of the foundation was to bring about initiatives and projects that will help the people of the communities that will be served.
Eric Lefkofsky is a man who ever wants people to have a comfortable life and a bright future. Due to this, he has decided to greatly invest in young people and help those who lack financial support. The help propels these people to reach their destinies or achieve their goals.
Lefkofsky has a passion for improving children’s health. The passion he has made him be appointed as a trustee of Lurie Children’s Hospital of Chicago. He is also a co-founder of the Lightbank. The company is a venture fund that has greatly invested in disruptive technology. The investment looks at improving people’s lives in terms of technology.
He is among the people who founded the company called Groupon. The company concentrates in the e-commerce market. It has helped people get products and services online. He has also gone ahead to become the co-founder of Mediaocean. The company is a media procurement technology which is highly appreciated by most people in the USA.
Cancer is caused by environmental as well as generic factors. One of the leading environmental causes of cancer is smoking tobacco. The interaction between genes and smoking has been concluded to play a significant role in the development of lung cancer.
Yafang Li, PhD, has been leading a team of researchers from Dartmouth in this field. The researchers have recently discovered three new single-nucleotide polymorphisms (SNPs). Essentially, SNPs are variations in human body’s DNA that are associated with a person’s susceptibility to developing certain diseases such as cancer.
The researchers used phenotype and genotype data from OncoArray Consortium to conduct the study. To improve their analysis, the researchers adopted a two-step strategy in a bid to reduce power often lost through ordinary gene environment interaction analysis.
According to the researchers, the three new SNPs may be used as biomarkers for scientists to use when categorizing individuals’ risks of developing lung cancer as a consequence of one’s genetics interactions with smoking. Overall, the SNPs are expected to improve the prognosis, diagnosis, and treatment of lung cancer in the near future. They may also set pace for research in other common forms of cancer associated with smoking and other environmental risks.
This research is reportedly the largest of its kind, according to Yafang. However, it is important to note that all the participants were of Caucasian origin. Considering that people from different races have variations in their genetic makeup, the results of this research may be largely limited only to the Caucasian population. However, the team of researchers is making plans to conduct similar research on people from other races in a bid to reduce any inconsistencies in findings. What’s more, the researchers promise to improve their findings as they collect more data on gene-smoking interaction.
A report detailing this research was published in the journal Carcinogenesis under the title Genome-wide interaction study of smoking behavior and non-small cell lung cancer risk if Caucasian population.
Tempus is an upcoming health startup that is focusing on devising better ways to fight cancer. The firm claims to work with scientists and physicians to analyze patients’ genetic code in respect to molecular therapy. By collecting and analyzing genomic data, Tempus hopes to improve precision and personalization in the diagnosis and treatment of cancer.
Tempus is currently on lung, breast, and pancreatic cancer, but plans are underway to study other common types of cancer.
Oncotarget is a peer based research journal which covers research on the different aspects of oncology. It was established in 2010, and the renowned impact journals publish their work. Oncotarget journals are an open source since everyone is allowed to access them or even give submissions to aid in their research.In depth, Oncotarget focuses on the existence of cancer-based on pathological studies. Potential patients who are required to be subjected to therapies and methods of cancer treatment to be employed are also key issues explained in this journal. It also looks at the new therapeutic agents and their capacity to manage programs for the cancer patients.
This journal explores the origin of new therapies and also focuses on the existing ones. The journal explains how these therapies can be improved to ensure a positive outcome of the patient. Importantly, it reveals the usage of these treatments, the ultimate employment of them and the response given to the cancer patients as well as the medical professional.Under the ultimate management by experienced scientists in the medical fields, the journal has given a chance to all researchers to contribute to the progress of scientific data. The journal welcomes any submitted papers which cover the original research. Basic science, epidemiological science, clinical reviews, and evaluations have gotten a chance in the scientific research industry through Oncotarget.
Oncotarget has had the opportunity to submit journals based on blood and lymphatic cancers. In the identification of targets for therapies and optimizing the usage of integrated modes of treatment to optimize preventive measures and improve the survival of the patient. Oncotarget has been able to improve the quality of life for the patients. Their primary goal is to have a disease free world and most of their studies have been proven success by many scientific research institutions.The journal has also discussed the use of oncolytic viruses to treat cancer. This has emerged as a treatment method that uses the propagation of viruses which are competitive in the treatment of cancer. Identification of drugs that improve the production of viruses has acted as a new strategy to boost the use of oncolytic viruses. The firm has also been involved in research on breast cancer and gastrointestinal cancer.